- Open Access
Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
Journal for ImmunoTherapy of Cancer volume 7, Article number: 9 (2019)
- The original article was published in Journal for ImmunoTherapy of Cancer 2018 6:101
Correction to: Journal for ImmunoTherapy of Cancer (2018) 6:101
Following publication of the original article , the authors reported an error in their listed affiliations.
In this Correction Dr. Jiaxin Zhao is related to two affiliations:
1. The Second Affiliated Hospital & Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou, China.
3. The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
The published apologizes for any inconvenience caused by this error.
Zhao, et al. Journal for ImmunoTherapy of Cancer. 2018;6(101). https://doi.org/10.1186/s40425-018-0421-z.
About this article
Cite this article
Zhao, B., Zhao, H. & Zhao, J. Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients. j. immunotherapy cancer 7, 9 (2019). https://doi.org/10.1186/s40425-018-0487-7